HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]
HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Intended Retirement of Independent Non-executive Director and changes of composition of board committees